

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2024

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-33137
(Commission File Number)

14-1902018
(IRS Employer
Identification No.)

**300 Professional Drive,
Gaithersburg, Maryland 20879**

(Address of principal executive offices, including zip code)

(240) 631-3200
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|-------------------|---|
| Common Stock, \$0.001 par value per share | EBS | New York Stock Exchange |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On December 16, 2024, Emergent BioSolutions Inc. (“Emergent”) announced that it received a contract option modification (“Modification No. 18”) of the BARDA AV7909 Contract (as defined below) from from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUST™ (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as “AV7909”) valued at \$50 million. This modification relates to Emergent’s AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority, which became effective on September 30, 2016 (the “BARDA AV7909 Contract”) and has been modified from time to time.

The preceding description of Modification No. 18 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 18, filed as Exhibit 10.1 to this Current Report. The BARDA AV7909 Contract was filed as Exhibit 10.2 to Emergent’s Quarterly Report on Form 10-Q for the period ended September 30, 2016, which was filed with the U.S. Securities and Exchange Commission on November 9, 2016.

On January 8, 2025, the Company announced the exercise of a contract option and modification (“Modification No. 3”) to the indefinite-delivery, indefinite-quantity (IDIQ) procurement contract (the “BioThrax IDIQ Contract”) with the U.S. Department of Defense and led by The Joint Program Executive Office for Chemical, Biological Radiological and Nuclear Defense (JPEO-CBRND), valued at approximately \$20 million to supply Emergent’s product BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.

The preceding description of Modification No. 3 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 3, filed as Exhibit 10.2 to this Current Report. The BioThrax IDIQ Contract was filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, which was filed on May 2, 2024.

On December 16, 2024, and January 8, 2025, Emergent issued press releases announcing the respective contract modifications as discussed above. Copies of the press releases are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report and incorporated herein by reference

Item 9.01 Financial Statements and Exhibits.

(d) *Exhibits.*

| Exhibit No. | Description |
|--------------------|---|
| 10.1 | Modification No. 18, effective December 12, 2024, to the BARDA AV7909 Contract. |
| 10.2 | Modification No. 3, effective December 13, 2024, to the BioThrax IDIQ Contract. |
| 99.1 | Press release issued by Emergent BioSolutions Inc. on December 16, 2024. |
| 99.2 | Press release issued by Emergent BioSolutions Inc. on January 8, 2025. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EMERGENT BIOSOLUTIONS INC.

Dated: January 8, 2025 By: _____ /s/ Richard S. Lindahl
Name: Richard S. Lindahl
Title: Executive Vice President, Chief Financial
Officer and Treasurer

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.

| | | | |
|--|------------------------------------|---|--|
| AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT | | 1. CONTRACT ID CODE | PAGE OF PAGES 1 3 |
| 2. AMENDMENT/MODIFICATION NO. P00018 | 3. EFFECTIVE DATE See Block 16C | 4. REQUISITION/PURCHASE REQ. NO. ASP337157 | 5. PROJECT NO. (If applicable) |
| 6. ISSUED BY ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 | CODE ASPR-BARDA | 7. ADMINISTERED BY (If other than Item 6) ASPR-BARDA 200 Independence Ave., S.W. Room 638-G Washington DC 20201 | CODE ASPR-BARDA |
| 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. EMERGENT PRODUCT DEVELOPMENT GAITHE 300 PROFESSIONAL DR # 100 GAITHERSBURG MD 208793419 | | (X) 9A. AMENDMENT OF SOLICITATION NO. | 9B. DATED (SEE ITEM 11) |
| CODE 1365869 | FACILITY CODE | X 10A. MODIFICATION OF CONTRACT/ORDER NO. HHSO100201600030C | 10B. DATED (SEE ITEM 13) 09/30/2016 |

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended. is not extended.
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)
2025.Q99BS25.26088 Net Increase: \$50,000,000.00

13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

| | |
|-----------|---|
| CHECK ONE | A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. |
| | B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). |
| X | C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: FAR Part 43.103(a) - Bilateral Modifications |
| | D. OTHER (Specify type of modification and authority) |

E. IMPORTANT: Contractor is not is required to sign this document and return 1 copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Tax ID Number: [**]

UEI: CNPVC8DK7M8

The purpose of this modification is to exercise CLIN 0011D and update ARTICLE B.3. OPTION PRICES.


Funds Obligated Prior to this Modification: \$[**]
Funds Obligated with Mod #18: \$[**]
Total Funds Obligated to Date: \$[**]

All other terms and conditions remain unchanged.

OTA: N

Continued ...

Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.

| | | | | | |
|--|--|--|---|--|--|
| 15A. NAME AND TITLE OF SIGNER (Type or print) Paul Williams SVP, Products Business | 15B. CONTRACTOR/OFFEROR  (Signature of person authorized to sign) | 15C. DATE SIGNED Date: Dec 12, 2024 11:58 EST | 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Yifan Yang - Digitally signed by Yifan Yang - S YIFAN YANG | 16B. UNITED STATES OF AMERICA S (Signature of Contracting Officer) | 16C. DATE SIGNED Date: 2024.12.12 13:22:07 -05'00' |
|--|--|--|---|--|--|

Previous edition unusable

CONTINUATION SHEET

REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201600030C/P00018

PAGE OF
2 3

NAME OF OFFEROR OR CONTRACTOR
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 1365869

| ITEM NO. (A) | SUPPLIES/SERVICES (B) | QUANTITY (C) | UNIT (D) | UNIT PRICE (E) | AMOUNT (F) |
|-----------------|--|-----------------|-------------|-------------------|---------------|
| 14 | Appr. Yr.: 2025 CAN: Q99BS25 Object Class: 26088 Period of Performance: 09/30/2016 to 08/31/2025 Add Item 14 as follows: CLIN 0011D Additional Surge Capacity (Licensure) | | | | [**] |

The purpose of this modification is to modify ARTICLES B.3 OPTION PRICES, B.5. ADVANCE UNDERSTANDINGS, ARTICLE C.1. STATEMENT OF WORK, and SECTION J- LIST OF ATTACHMENTS

ARTICLE B.3. OPTION PRICES – CLIN 0011 is modified as follows:

| CLIN | Period of Performance | Supplies/ Services | Estimated Doses | Price per Dose | Total Not to Exceed Cost |
|----------------------------|----------------------------|---------------------------------------|-----------------|--|--------------------------|
| 0011D (Option Quantity) | 12/9/2024 through 5/1/2025 | Additional Surge Capacity (Licensure) | [**] | \$[**] (> [**] months but ≤ [**] months from date of manufacture) | \$[**] (Funded) |
| | | | [**] | \$ [**] (≤ [**] months from date of manufacture) | |

ARTICLE B.5. ADVANCE UNDERSTANDINGS – is modified as follows:

p. CLIN 0011D

- For CLIN 0011D, BARDA agrees to receiving doses that are more than [**] months but not exceeding [**] months from their date of manufacture (Reduced Shelf-Life Doses)
- These anthrax vaccine doses will have two different unit prices depending on the age of the vaccine post-manufacture. Vaccine doses delivered up to or equal to [**] months from their manufacture date will be charged a dose price of \$[**] per dose. Vaccines delivered with a reduced shelf life greater than [**] months, but less than or equal to [**] months post-manufacture will be charged a unit dose price of \$[**] per dose.

The following table is provided as an estimate of doses to be delivered under CLIN 011D but subject to change:

| Product | Period of Performance | Estimated Quantity for Delivery |
|--------------------------|---|---------------------------------|
| Base Doses | ≤ months from date of manufacture | [**] |
| Reduced Shelf-Life Doses | > [**] ≤ [**] months from date of manufacture | [**] |

End of Modification #18

ATTACHMENT 1: STATEMENT OF WORK
NEXT GENERATION ANTHRAX VACCINE RFP 16-100-
SOL-0015
AV7909 Anthrax Vaccine

1.0 Contractual Statement of Work

Preamble to the Statement of Work

Independently and not as an agent of the Government, the Contractor shall be required to furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government, as needed to perform the Statement of Work submitted in response to RFP 16-100-SOL- 00015.

1.1 Scope

The scope of work for this contract includes AV7909 development activities through licensure that fall into the following areas: program management, nonclinical, clinical, regulatory, and chemistry, manufacturing, and controls (CMC). The scope of work also includes activities to support post-marketing requirements.

1.2 Objective

The objective of this Statement of Work (SOW) is to conduct all necessary activities to advance the development of AV7909 through Biologics License Application (BLA) submission and approval and post- marketing requirements. Activities to meet the objective of this SOW fall in the following contract line item numbers (CLIN):

- CLIN 0001 – Approval of Emergency Use Authorization (EUA), licensure, approval, and clearance of product through the FDA (Base)
- CLIN 0001A – Conduct of a Phase 2 clinical [**] study or other studies required by the FDA for the establishment of a [**] specification (Option)
- CLIN 0012 Include doxycycline arm in the conduct of the Phase 2 clinical drug-drug interaction study and qualify a redundant contract filler (Base)
- CLIN 0002 – Initial purchase, storage, and delivery of product (Base)
- CLIN 0003 Phase 4 post marketing requirements (Option) –
- CLIN 0004 -Surge Capacity Additional procurement of product (EUA) (Option) [**] –
- CLIN 0006_ Surge Capacity Additional procurement of product (EUA) (Option) [**]doses
- CLIN 0010 Surge Capacity - Additional procurement of product (EUA) (Option) [**] or more doses
- CLIN 0011A Surge Capacity - Additional procurement of product (EUA and Licensed) (Option) up to [**] doses
- CLIN 0011B Surge Capacity - Additional procurement of product (Licensed) (Option)_ [**] doses
- CLIN 0011C Surge Capacity - Additional procurement of product (Licensed) (Option)_ [**] doses
- CLIN 0011D Surge Capacity - Additional procurement of product (Licensed) (Option)_ [**] doses

AV7909 Target Delivery Schedule (CLIN 0011A)

| | | |
|------------|-----------|---------|
| Q2 2023 | Q3 2023 | Q4 2023 |
| Apr – Jun | Jul – Sep | Oct |
| [**] doses | | |

Cyfendus Target Delivery Schedule (CLIN 0011B)

| |
|-------------------|
| Q4 2023 – Q1 2024 |
| Nov - Mar |
| [**] doses |

Cyfundus Target Delivery Schedule (CLIN 0011C)

| |
|------------|
| Q2 2024 |
| June |
| [**] doses |

Cyfundus Target Delivery Schedule (CLIN 0011D)

| |
|------------|
| Q1 2025 |
| Nov - May |
| [**] doses |

1.3 CLIN 0001 - Approval of Emergency Use Authorization (EUA), licensure, approval, and clearance of product through the FDA (Base)

This section identifies representative tasks and sub-tasks for CLIN 0001 with associated WBS code for each task or subtask.

[] Program Management**

Emergent shall provide program management activities. The activities shall include but are not limited to:

- Identification of and management to, distinct stages of the product development pathway that are gates for Go/No Go decisions for advancing to the next stage of the Integrated Product Development Plan.
- Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of product development activities for each stage with a budget (in direct costs) linked to each stage.
- Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the scientific merit and technical feasibility of proceeding to the next stage of product development.
- Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated effort to perform the work.
- Directing and overseeing subcontractors and consultants to assure successful performance of planned activities within the cost and schedule constraints of the contract.
- Conducting performance measurement that shall include establishing an initial plan; defining measurable parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a detailed schedule that generates a critical path for the project; and a description of the cost-accounting system used or intended to be used based on budget estimates to monitor all costs related to the contract award for both Emergent and subcontractors on a real time basis.
- Manage contract activities in accordance with Earned Value Management. In this regard, Emergent shall:
 - Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly indicates the critical path to support product approval. The Integrated Master Project Plan shall outline key, critical path milestones, with "Go/No-Go" decision criteria and a contract Work Breakdown Structure (due within 90 days of contract award with updates as requested by the Contracting Officer's Representative (COR).
 - Submit an updated Integrated Master Schedule in an approved format.

- Use principles of Earned Value Management System (EVMS) in the management of this contract.
- Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award.
- Develop and maintain a risk management plan.
- Participate in regular meetings to coordinate and oversee the contracting effort.

[] Non-Clinical Toxicology**

Emergent shall conduct safety and toxicology of AV7909 using animal models following Good Laboratory Practice guidelines (GLP: as defined in the U.S. Code of Federal Regulations, 21CFR Part 58), as appropriate. The activities shall include but are not limited to:

- [**]
- [**]

[] Non-Clinical Efficacy**

Emergent shall conduct efficacy, pharmacokinetics/pharmacodynamics, bioavailability, solubility, formulation, dose, route and schedule of the medical countermeasure using both in vitro and animal models following Good Laboratory Practice guidelines (GLP: as defined in the U.S. Code of Federal Regulations, 21 CFR Part 58), as appropriate. The activities shall include but are not limited to:

- [**]
- [**]

[] Clinical Evaluation**

Emergent shall design and conduct Phase 2 and Phase 3 clinical studies in accordance with all Federal regulations and Good Clinical Practice (GCP) guidelines. The activities shall include but are not limited to:

- [**]
- [**]

[] Regulatory Activities**

Emergent shall conduct all required regulatory activities to support submission of BLA licensure for AV7909. The activities shall include but are not limited to:

- [**]

-

[] - Chemistry and Manufacturing Controls (CMC)**

Emergent shall complete the manufacturing activities necessary to support BLA submission. The activities shall include but are not limited to:

- [**]

[] - Phase 4 post-marketing requirement:**

[]**

1.4 CLIN 0001A - Conduct of a Phase 2 clinical [] study or other studies required by the FDA for the establishment of a [**] (Option)**

This section identifies representative tasks and sub-tasks for CLIN 0001A with associated WBS code for each task or subtask.

[] Program Management**

Emergent shall provide program management activities. The activities shall include but are not limited to:

- Identification of and management to, distinct stages of the product development pathway that are gates for Go/No Go decisions for advancing to the next stage of the Integrated Product Development Plan.
- Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of product development activities for each stage with a budget (in direct costs) linked to each stage.
- Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the scientific merit and technical feasibility of proceeding to the next stage of product development.
- Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated effort to perform the work.
- Directing and overseeing subcontractors and consultants to assure successful performance of planned activities within the cost and schedule constraints of the contract.
- Conducting performance measurement that shall include establishing an initial plan; defining measurable parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a detailed schedule that generates a critical path for the project; and a description of the cost-accounting system used or intended to be used based on budget estimates to monitor all costs related to the contract award for both Emergent and subcontractors on a real time basis.
- Manage contract activities in accordance with Earned Value Management. In this regard, Emergent shall:
 - Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that

clearly indicates the critical path to support product approval. The Integrated Master Project Plan shall outline key, critical path milestones, with "Go/ No Go" decision criteria and a contract Work Breakdown Structure (due within 90 days of contract award with updates as requested by the Contracting Officer's Representative (COR).

- Submit an updated Integrated Master Schedule in an approved format.
- Use principles of Earned Value Management System (EVMS) in the management of this contract.
- Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award.
- Develop and maintain a risk management plan.
- Participate in regular meetings to coordinate and oversee the contracting effort.

[] Clinical Evaluation**

Emergent shall design and conduct a Phase 2 clinical study in accordance with all Federal regulations and Good Clinical Practice (GCP) guidelines unless other studies are required by the FDA for the establishment of [**]. The activities shall include, but are not limited to:

- [**]

[] - Chemistry and Manufacturing Controls (CMC)**

Emergent shall complete the manufacturing activities necessary to support AVA.214 Phase 2 [**] Spec Study. The activities below are specific to conducting a Phase 2 [**] clinical study. If the FDA requires an alternate strategy for establishment of [**], the activities below may no longer be applicable. Upon new guidance from the FDA, Emergent will update the SOW accordingly.

- [**]

[] Include doxycycline arm in the conduct of the Phase 2 clinical drug-drug interaction study and qualify a redundant contract filler (Base)**

This section identifies representative activities of CLIN 0012 associated with CLIN0001 subtask [**] and task [**]

- [**]

–

1.6 CLIN 0002 - Initial purchase, storage, and delivery of product (Base)

Under the Base Period funding Emergent shall manufacture, fill, and deliver [**] doses procured in fiscal year 2019 as an initial procurement to the Strategic National Stockpile (SNS). Emergent is approved to use management reserve funding for shipping costs associated with these deliveries.

1.7 CLIN 0003 - Phase 4 post marketing requirements (Option)

Reclassified to CLIN 0001. See [**] under CLIN 0001 for details.

Program Management

Emergent shall provide program management activities. The activities shall include but are not limited to:

- Identification of and management to, distinct stages of the product development pathway that are gates for Go/No Go decisions for advancing to the next stage of the Integrated Product

Development Plan.

- Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of product development activities for each stage with a budget (in direct costs) linked to each stage.
- Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the scientific merit and technical feasibility of proceeding to the next stage of product development.
- Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated effort to perform the work.
- Directing and overseeing subcontractors and consultants to assure successful performance of planned activities within the cost and schedule constraints of the contract.
- Conducting performance measurement that shall include establishing an initial plan; defining measurable parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a detailed schedule that generates a critical path for the project; and a description of the cost-accounting system used or intended to be used based on budget estimates to monitor all costs related to the contract award for both Emergent and subcontractors on a real time basis.
- Manage contract activities in accordance with Earned Value Management. In this regard, Emergent shall:
 - Provide an Integrated Master Project Plan (including tabular and Gantt forms) to BARDA that clearly indicates the critical path to support product approval. The Integrated Master Project Plan shall outline key, critical path milestones, with "Go/No Go" decision criteria and a contract Work Breakdown Structure (due within 90 days of contract award with updates as requested by the Contracting Officer's Representative (COR).
 - Submit an updated Integrated Master Schedule in an approved format.
 - Use principles of Earned Value Management System (EVMS) in the management of this contract.
 - Submit a plan for a Performance Measurement Baseline Review (PMBR) electronically via email to the Contracting Officer (CO) and COR for a PBMR to occur within 90 days of contract award.
- Develop and maintain a risk management plan.
- Participate in regular meetings to coordinate and oversee the contracting effort.

[**]

1.8 CLIN 0004 through 11 - Surge Capacity Additional procurement of product (Option)

Emergent shall deliver up to [**] dose regimens (equivalent to [**] doses of AV7909). This option may be triggered after EUA pre-authorization approval by FDA, which is currently linked to release of PPQ lots, and deliveries will start within six months after trigger.

Under CLIN 0004, Emergent shall manufacture, fill, and deliver [**] doses procured in fiscal year 2019

as an initial procurement to the Strategic National Stockpile (SNS). Emergent will be responsible for shipping and transport of filled and finished AV7909 product to the SNS and the costs associated with the delivery.

Under CLIN 0006 Emergent shall manufacture, fill, and deliver [**] doses procured from [**] through [**], as an additional procurement to the SNS. Emergent will be responsible for shipping and transport of filled and finished AV7909 product to the SNS and the costs associated with the delivery.

For CLINs 0004 and 00006, BARDA may accept "Short Dated Doses" (doses dated [**] months but [**] months from the date of manufacture if such doses are delivered along with the appropriate number of additional doses ("Additional Doses"). Additional Doses shall be calculated at [**]% of the number of delivered Short Dated Doses (e.g. [**] Short Dated Doses + [**] Additional Doses for a total delivery of [**] doses).

For CLIN 0011A, BARDA agrees to accept "Reduced Shelf-Life Doses" (doses dated [**] months but [**] months from the date of manufacture) at a discounted price.

These anthrax vaccine doses will have two different unit prices depending on the age of the vaccine post-manufacture. Vaccine doses delivered up to or equal to [**] months from their manufacture date will be charged a dose price of \$[**] per dose. Vaccines delivered with a reduced shelf life [**] months, but [**] months post-manufacture will be charged a unit dose price of \$[**] per dose. BARDA will not accept any vaccine older than [**] months post-manufacture.

For CLIN 0011B, Emergent shall provide [**] doses, dated less than or equal to [**] months from the date of manufacture (\geq [**] month shelf life at month of delivery at \$[**] per dose between [**] through [**]).

For CLIN 0011C, Emergent shall provide [**] doses, dated less than or equal to [**] months from the date of manufacture (\geq [**] month shelf life at month of delivery) at \$[**] per dose and [**] doses, dated less than or equal to [**] months from the date of manufacture (\geq [**] month shelf life at month of delivery).

For CLIN 0011D, Emergent shall provide an estimated [**] doses, dated less than or equal to [**] months from the date of manufacture (\geq [**] month shelf life at month of delivery) at \$[**] per dose and an estimated [**] doses, dated less than or equal to [**] months from the date of manufacture (\geq [**] month shelf life at month of delivery).

For delivery to the SNS, Emergent shall comply with the relevant associated activities and deliverables as outlined in the Quality Agreement (attached) as signed by Emergent, BARDA, and the SNS. Emergent shall provide appropriate documentation to BARDA for quality assurance of the final drug product delivered to the SNS and invoice appropriately.

1.9 Reporting Requirements and Deliverables Reports

As part of the work to be performed under this contract, Emergent will prepare and deliver the following reports throughout the period of performance.

Monthly Technical Progress Reports

On the fifteenth (15) day of each month for the previous calendar month, Emergent will submit to the COR and the CO a Technical Progress Report covering the previous calendar month. The first reporting period consists of the first full month of performance plus any fractional part of the initial month.

Thereafter, the reporting period will consist of each calendar month. The frequency of Technical Progress Reporting will be determined by the CO and COR during negotiations of the contract. The format and type of Technical Progress Report and Executive Summary will be provided by the COR. The Technical Progress Reports will summarize progress for the reporting period, such as: management and administrative updates,

technical progress, issues, proposed work, manufacturing and supply chain management, and a summary of invoices. A Technical Progress Report will not be required for the period when the same month Annual Progress Reports or a Final Report are due. Emergent will submit one copy of the Technical Progress Report electronically via e-mail to the CO and COR.

Annual Progress Reports

On the thirtieth (30th) calendar day following the last day of each reporting period, Emergent will submit to the COR and the CO an Annual Progress Report. The first reporting period consists of the first full year of performance plus any fractional part of the initial year. Thereafter, the reporting period shall consist of each calendar year. Annual Progress Reports will summarize progress for the reporting period, such as: management and administrative updates, technical progress, issues, proposed work, manufacturing and supply chain management, and a summary of invoices. An Annual Progress Report will not be required for the period when the Final Technical Progress Report is due.

Draft Final Report and Final Report

Emergent will submit the Draft Final Progress Report forty-five (45) calendar days prior to the expiration date of the contract and the Final Progress Report on or before the expiration date of the contract. These reports will include a summation of the work performed and results obtained for execution of various studies or technical work packages during the entire contract period of performance. This report will be in sufficient detail to describe comprehensively the results achieved. An electronic copy of the Draft Final Report and Final Report will be submitted to the COR and CO.

FDA Regulatory Agency Correspondence, Meeting Summaries, and Submissions

With regard to interactions with the FDA, Emergent shall:

- Forward the initial draft minutes to BARDA within five business days of any formal meeting with the FDA or other regulatory agency, and forward the final minutes when available.
- Forward the initial draft minutes to BARDA within five business days of any informal meeting with the FDA or other regulatory agency, and forward the final minutes when available and if applicable.
- Forward the dates and times of any meeting with the FDA and other regulatory agencies to BARDA as soon as the meeting times are known and make arrangements for appropriate BARDA staff to attend the meetings.
- Provide BARDA the opportunity to review and comment upon any documents to be submitted to the FDA or other regulatory agency. Emergent will provide BARDA with five (5) business days in which to review and provide comments prior to Emergent's submission to the FDA.

Emergent will notify the COR and CO within 24 hours of all FDA arrivals to conduct site visits/audits by any regulatory agency and provide the USG with an exact copy (non-redacted) of the FDA Form 483 and the Establishment Inspection Report (EIR). Emergent will provide the COR and CO copies of the plan for addressing areas of non-conformance to FDA regulations for Good Laboratory Practice (GLP) guidelines as identified in the audit report, status updates during the plan's execution, and a copy of all final responses to the FDA. Emergent will also provide redacted copies of any FDA audits received from subcontractors that occur as a result of this contract or for this product. Emergent will make arrangements with the COR for the appropriate BARDA representative(s) to be present during the final debrief by the regulatory inspector.

Key Deliverables


A summary of Key Deliverables for this contract follow

| No. | Deliverable | Description | Due Date |
|-----|--|---|--|
| 01 | Monthly Progress Report | Shall include a description of the activities during the reporting period and the activities planned for the ensuing reporting period. The first reporting period consists of the first full month of performance plus any fractional part of the initial month. Thereafter, the reporting period shall consist of each calendar month. | Due on or before the 15th day of each month following the end of each reporting period. Monthly progress reports are not required in the same month Annual Progress reports or a Final Report are due. |
| 02 | Annual Progress Report | Shall include a summation of the activities during the reporting period, and the activities planned for the ensuing reporting period. The first reporting period consists of the first full year of performance plus any fractional part of the initial year. Thereafter, the reporting period shall consist of each calendar year. | Due on or before the 30 th calendar day following the end of each reporting period. |
| 03 | Draft Final Progress Report | To include a summation of the work performed and results obtained for execution of various studies or technical work packages during entire contract period of performance. Shall be in sufficient detail to describe comprehensively the results achieved. | Due 45 Calendar days prior to the expiration date of the contract. |
| 04 | Final Progress Report | To include a summation of the work performed and results obtained for execution of various studies or technical work packages during entire contract period of performance. Shall be in sufficient detail to describe comprehensively the results achieved. | Due on/before the expiration date of the contract. |
| 05 | FDA/Regulatory Agency Correspondence and Meeting Minutes | The Contractor shall forward initial draft minutes and final draft minutes of any formal or informal meeting with the FDA or other regulatory agency. The contractor shall forward the dates and times of any meeting with the FDA and other regulatory agencies as soon as the meeting times are known and make arrangements for appropriate BARDA staff to attend the meetings. The Contractor shall provide BARDA the opportunity to review and comment upon any documents to be submitted to the FDA or other regulatory agency. The Contractor shall forward SOPs upon request from the COR. The contractor shall notify the COR and CO within 24 hours of all FDA arrivals to conduct site visits/audits by any regulatory agency, and provide copies of any associated reports, documentation, or communication. | Due within 5 business days of each meeting for Contractor's minutes, upon receipt of minutes from FDA/regulatory agency, and upon request from the COR or Co-COR. |
| 06 | Integrated Master Project Plan (Critical Path Milestones, Work Breakdown Structure, Risk Mitigation Plan/Matrix) | The contractor shall provide an Integrated Master Plan (including tabular and Gantt forms) to BARDA that clearly indicates the critical path to annual deliverables (key, critical path milestones, with "Go/No Go" decision criteria) and Work Breakdown Structure (WBS) elements that shall be discernable and consistent. The contractor shall develop and maintain a risk management plan that highlights potential problems and/or issues that may arise during the life of the contract, their impact on cost, schedule and performance, and appropriate remediation plans. | Due within 90 days of contract award. Updates are due as requested by the COR or Co-COR. |

| | | | |
|----|---|---|---|
| 07 | Technology Packages | Technology packages developed under the contract that includes complete protocols must be submitted at the request of the BARDA COR. | Due upon request from the COR or Co-COR. |
| 08 | Experimental Protocols | The Contractor shall submit to the COR all study/experiment/test plans, designs, and protocols prior to execution for BARDA approval or upon request by the COR or Co-COR when required. | Due upon request from the COR or Co-COR. |
| 09 | Annual/Final Invention Report | All reports and documentation required by FAR Clause 52.227-11, Patent Rights-Ownership by the Contractor, including, but not limited to, the invention disclosure report, the confirmatory license, and the Government support certification. If no invention is disclosed or no activity has occurred on a previously disclosed invention during the applicable reporting period, a negative report shall be submitted to the CO. | Annual Invention Report Due on or before the 30th calendar day after the completion of each reporting period. Final Invention Report due on or before the expiration of the contract. |
| 10 | Publications | Any manuscript or scientific meeting abstract containing data generated under this contract must be submitted to COR for review prior to submission. | Due within 30 calendar days for manuscripts prior to publication and 15 calendar days for abstracts. |
| 11 | Press Releases | The Contractor agrees to accurately and factually represent the work conducted under this contract in all press releases. The Contractor shall ensure the CO has received and approved an advanced copy of any press release not less than five (5) business days prior to the issuance of any potential press release. | Reports/Notices due for approval to the CO not less than five (5) business days prior to the issuance of any potential press release. |
| 12 | Security Report | The contractor shall report to the government any activity or incident that is in violation of established security standards or indicates the loss or theft of government products | Due within 24 hours after occurrence of an activity or incident. |
| 13 | Earned Value Management System Requirements | Subject to the requirements under FAR 52.234-4 Earned Value Management System, the Contract shall use principles of Earned Value Management System (EVMS) in the management of this contract (include this plan as part of the monthly, annual, and final reports). The Contractor shall also submit a Performance Measurement Baseline Review plan electronically via email to the CO and COR for a PMBR to occur within 90 days of contract award, and an Integrated Master Schedule electronically via email as outlined in a format agreed upon by BARDA to the COR and CO. The Offeror shall deliver an Earned Value Contract Performance Report on a monthly basis. | As detailed in Section F.3.2 Subpart F.No Longer Required from the period starting 10/01/2023 onward. |

| | Milestone # | WBS # | Milestone | Deliverables Summary (Details as specified in the Deliverables) | Quantity | Estimated Completion Date |
|-----------------------|-------------|-------|-----------|---|--|---------------------------|
| CLIN 0001 & CLIN 0012 | 1 | [**] | [**] | [**] | 1 Electronic Copy to Contract Officer Representative (COR); 1 Electronic Copy to Contracting Officer (CO) | 12/19/2017 |
| | 2 | [**] | [**] | [**] | See Above | 1/18/2018 |
| | 3 | [**] | [**] | [**] | See Above | 5/24/2018 |
| | 4 | [**] | [**] | [**] | See Above | 11/6/2018 |
| | 5 | [**] | [**] | [**] | See Above | 11/8/2018 |
| | 8 | [**] | [**] | [**] | See Above | 3/21/2021 |
| | 9 | [**] | [**] | [**] | See Above | 8/18/2020 |
| | 10 | [**] | [**] | [**] | See Above | 12/31/2021 |
| | 11 | [**] | [**] | [**] | See Above | 5/12/2021 |
| | 12 | [**] | [**] | [**] | See Above | 12/15/2021 |
| | 16 | - | [**] | [**] | See Above | 10/24/2019 |
| | CLIN 0002 | | | | | |

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.

| | | | | |
|--|----------------------------------|---|---|------------------------|
| AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT | | | I. CONTRACT ID CODE | PAGE OF PAGES 1 4 |
| 2. AMENDMENT/MODIFICATION NO. P00003 | 3. EFFECTIVE DATE 13-Dec-2024 | 4. REQUISITION/PURCHASE REQ. NO. SEE SCHEDULE | 5. PROJECT NO.(If applicable) | |
| 6. ISSUED BY USA CONTRACTING CMD-APG - W911SR EDGEWOOD CONTRACTING DIVISION 8456 BRIGADE STREET BLDG E4215 ABERDEEN PROVING GROUND MD 21010-5401 | CODE W911SR | 7. ADMINISTERED BY (If other than item 6) See Item 6 | | |
| 8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) EMERGENT BIODEFENSE OPERATIONS LANSING L EMERGENT BIODEFENSE 3500 N MARTIN LUTHER KING JR BLVD LANSING MI 48906-2933 | | 9A. AMENDMENT OF SOLICITATION NO. | | |
| | | 9B. DATED (SEE ITEM 11) | | |
| | | X 10A. MOD. OF CONTRACT/ORDER NO. W911SR24F0016 | | |
| | | X 10B. DATED (SEE ITEM 13) 22-Jan-2024 | | |
| CODE 1H0B6 | FACILITY CODE | | | |
| 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS | | | | |
| <input type="checkbox"/> The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of offer <input type="checkbox"/> is extended, <input type="checkbox"/> is not extended. Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. | | | | |
| 12. ACCOUNTING AND APPROPRIATION DATA (If required) See Schedule | | | | |
| 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. | | | | |
| A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. | | | | |
| B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). | | | | |
| X C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: FAR 52.217-9 Option to Extend the Terms of the Contract | | | | |
| D. OTHER (Specify type of modification and authority) | | | | |
| E. IMPORTANT: Contractor <input type="checkbox"/> is not, <input checked="" type="checkbox"/> is required to sign this document and return <u>1</u> copies to the issuing office. | | | | |
| 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Modification Control Number: mjohn1sr2514 The purpose of this modification to exercise Option CLIN 1001. | | | | |
| Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect. | | | | |
| 15A. NAME AND TITLE OF SIGNER (Type or print) Paul Williams SVP, Products Business | | 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Brian E. Mazen / Contracting Officer TEL: 520-671-3728 EMAIL: Brian.E.Mazen.civ@army.mil | | |
| 15B. CONTRACTOR/OFFEROR  Electronically signed by: Paul Williams Reason: I approve this document Date: Dec 11, 2024 12:23 EST (Signature of person authorized to sign) | 15C. DATE SIGNED | 16B. UNITED STATES OF AMERICA BY MAZEN.BRIAN.E.1387647780 (Signature of Contracting Officer) | 16C. DATE SIGNED Digitally signed by MAZEN.BRIAN.E.1387647780 Date: 2024.12.11 12:47:22 -05'00' | |

EXCEPTION TO SF 30
APPROVED BY OIRM 11-84

30-105-04

STANDARD FORM 30 (Rev. 10-83)
Prescribed by GSA
FAR (48 CFR) 53.243

SECTION SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES

SECTION SF 30 - BLOCK 14 CONTINUATION PAGE

The following have been added by full text:

P00003

The purpose of this modification is as follows:

1. To exercise Option CLIN 1001.
2. To provide incremental funding for Option CLIN 1001 in the amount of \$[**] to procure [**] doses of BioThrax® AVA (Anthrax Vaccine Absorbed).
3. Pursuant to DFARS 252.232-7007, Limitation of Government's Obligation, initial funding in the amount of \$[**] is hereby added to Contract Line Item Number (CLIN) 1001 as shown in the table below.

| CLIN | CLIN Amount | Current Funding | Total Funding | Balance to be funded |
|------|-------------|-----------------|---------------|----------------------|
| 1001 | \$[**] | \$[**] | \$[**] | \$[**] |

4. Except as provided herein, all terms and conditions remain unchanged.

SECTION SF 1449 - CONTINUATION SHEET

SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by \$[**] from \$[**] to \$[**].

SUPPLIES OR SERVICES AND PRICES

CLIN 1001

The option status has changed from Option to Option Exercised.

SUBCLIN 100101 is added as follows:

| ITEM NO | SUPPLIES/SERVICES | QUANTITY | UNIT | UNIT PRICE | AMOUNT |
|---------|---|----------|------|------------|--------|
| 100101 | Funding FFP Funding in support of CLIN 1001. PURCHASE REQUEST NUMBER: 0012227877 | | | | \$0.00 |

NET AMT \$0.00

ACRN AC \$[**]
CIN: GFEB001222787700001

ACCOUNTING AND APPROPRIATION

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$[**] from \$[**] to \$[**].

SUBCLIN 100101:
Funding on SUBCLIN 100101 is initiated as follows:

ACRN: AC
CIN: GFEB001222787700001
Acctng Data: 0212024202520400000665654255 A.0012510.9.2.5.7 6100.9000021001
Increase: \$[**]
Total: \$[**]
Cost Code: A5XAH

DELIVERIES AND PERFORMANCE

The following Delivery Schedule item for CLIN 1001 has been changed from:

| DELIVERY DATE | QUANTITY | SHIP TO ADDRESS | DODAAC / CAGE |
|---------------|----------|--|---------------|
| 31-JUL-2025 | [**] | MURTECH, INC MANN 820 CROMWELL PARK DR, STE J GLEN BURNIE MD 21061-2574 FOB: Origin (Shipping Point) | W56XNH |

To:

| DELIVERY DATE | QUANTITY | SHIP TO ADDRESS | DODAAC / CAGE |
|---------------|----------|--|------------------|
| 25-SEP-2025 | [**] | MURTECH, INC MANN 820 CROMWELL PARK DR, STE J GLEN BURNIE MD 21061-2574 FOB: Origin (Shipping Point) | W56XNH |

INSPECTION AND ACCEPTANCE

The following Acceptance/Inspection Schedule was added for SUBCLIN 100101:

| INSPECT AT | INSPECT BY | ACCEPT AT | ACCEPT BY |
|------------|------------|-----------|-----------|
| N/A | N/A | N/A | N/A |

(End of Summary of Changes)

Emergent BioSolutions Receives \$50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) – Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services has awarded a \$50 million option to Emergent's existing contract (HHSO100201600030C) for the acquisition of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted).

Deliveries are expected to begin this calendar year and be complete by April 2025. This award follows a [previously announced contract modification](#) of \$30.0 million to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) this year.

CYFENDUS® vaccine was approved by the U.S. Food & Drug Administration (FDA) in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age. Anthrax is a Tier 1 biological select agent due to its potential to be used for a bioterrorist incident and threat to public health and national security.

"An anthrax emergency continues to be a significant public health threat due to its ability to be easily disseminated, lethality, and potential for widespread impact," said Paul Williams, senior vice president, products head at Emergent. "This procurement award further bolsters anthrax preparedness and demonstrates Emergent's commitment to public health preparedness."

In addition to the CYFENDUS® vaccine, Emergent's anthrax franchise includes the BioThrax® vaccine, which continues to serve a critical purpose, as well as two treatments, Anthrasil® [Anthrax Immune Globulin Intravenous (Human)], a polyclonal antibody therapeutic, and raxibacumab, a monoclonal antibody therapeutic.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under contract HHSO100201600030C.

About CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)**Indication**

CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to *Bacillus anthracis* in persons 18 through 65 years of age when given with recommended antibacterial drugs.

The efficacy of CYFENDUS® vaccine for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax.

Important Safety Information

Contraindication: Do not take CYFENDUS® vaccine if you are allergic to CYFENDUS® vaccine, BioThrax® (Anthrax Vaccine Adsorbed) or any ingredient of the vaccine.

Allergic reactions: Appropriate medical treatment and supervision must be available after receiving CYFENDUS® vaccine to manage possible serious allergic reactions. Get medical help right away if you have any symptoms of a serious allergic reaction.

Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to CYFENDUS® vaccine.

Pregnancy: CYFENDUS® vaccine can cause fetal harm when administered to a pregnant individual. Before getting CYFENDUS® vaccine, tell your healthcare provider if you may be pregnant, plan to get pregnant soon, or are nursing a baby.

Adverse reactions: The most common adverse reactions reported were tenderness, pain, warmth, itching, swelling, redness, bruising, arm motion limitations, muscle aches, tiredness, headache, and fever.

U.S. Prescribing Information

The full Prescribing Information for CYFENDUS® vaccine can be found [here](#).

About Emergent BioSolutions At Emergent, our mission is to protect and enhance life. For 25 years, we've been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our [website](#) and follow us on [LinkedIn](#), [X](#), [Instagram](#), [Apple Podcasts](#) and [Spotify](#).

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the development, availability, and government procurement of CYFENDUS® vaccine and the continued development of Emergent's anthrax franchise, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "should," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:

Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:

Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

Emergent BioSolutions Announces Exercise of \$20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

GAITHERSBURG, Md., Jan. 8, 2024 (GLOBE NEWSWIRE) – Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately \$20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately \$7 million began in December 2024, and remaining deliveries are expected in 2025.

“We’re pleased to continue our work with the U.S. Department of Defense to supply BioThrax® to protect our nation’s service members who have a high risk of exposure to anthrax,” said Paul Williams, senior vice president, products head at Emergent. “This procurement ensures a continued supply of this important medical countermeasure to the U.S. military and demonstrates our commitment to delivering solutions that address our customers’ needs to prepare for public health threats.”

This option is under Emergent’s existing indefinite-delivery, indefinite-quantity (IDIQ) [procurement contract](#) (W911SR24D0001) with the DoD and led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to supply BioThrax® for use by all branches of the U.S. military as pre-exposure prophylaxis (PrEP) for anthrax disease.

On December 16, 2024, Emergent announced a [\\$50 million contract option](#) from the Biomedical Advanced Research and Development Authority (BARDA) to procure doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). In addition to BioThrax® and CYFENDUS®, Emergent’s anthrax franchise includes two treatments, Anthrasil® [Anthrax Immune Globulin Intravenous (Human)], a polyclonal antibody therapeutic, and raxibacumab, a monoclonal antibody therapeutic.

About BioThrax® (Anthrax Vaccine Adsorbed)**Indication**

BioThrax® (Anthrax Vaccine Adsorbed) is a vaccine indicated for the active immunization for the prevention of disease caused by *Bacillus anthracis* in persons 18 through 65 years of age.

BioThrax® is approved for: (1) Pre-exposure prophylaxis of disease in persons at high risk of exposure. (2) Post-exposure prophylaxis of disease following suspected or confirmed *Bacillus anthracis* exposure, when administered in conjunction with recommended antibacterial drugs.

The efficacy of BioThrax® for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax.

Important Safety Information

Contraindications: Severe allergic reaction (e.g., anaphylaxis) after a previous dose of BioThrax® or a component of the vaccine.

Latex: The stopper of the vial contains natural rubber latex and may cause allergic reactions in latex sensitive individuals.

Pregnancy: Avoid use in pregnancy unless the potential benefit outweighs the potential risk to the fetus.

History of Anthrax Disease: History of anthrax disease may increase the potential for severe local adverse reactions.

Altered Immunocompetence: If BioThrax® is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be diminished.

Limitations of Vaccine Effectiveness: Vaccination with BioThrax® may not protect all individuals.

Adverse reactions: The most common (>10%) local (injection-site) adverse reactions observed in clinical studies were tenderness, pain, erythema, edema, and arm motion limitation. The most common (≥5%) systemic adverse reactions were muscle aches, fatigue, and headache.

U.S. Prescribing Information

The full Prescribing Information for BioThrax® vaccine can be found [here](#).

About Emergent BioSolutions At Emergent, our mission is to protect and enhance life. For 25 years, we've been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our [website](#) and follow us on [LinkedIn](#), [X](#), [Instagram](#), [Apple Podcasts](#) and [Spotify](#).

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the development, availability, supply and government procurement of BioThrax® vaccine and the continued development of Emergent's anthrax franchise, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "should," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:

Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:

Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com